You Are Here    News

News
Several new candidates in HIV drug pipeline discussed at conference
Liz Highleyman, 2017-03-15 07:20

This year's Conference on Retroviruses and Opportunistic Infections (CROI 2017), held last month in Seattle, included presentations on several new investigational antiretroviral drugs in development, reflecting a more robust pipeline than we have seen in recent years.

Although modern antiretroviral therapy (ART) is highly effective and well tolerated by most people living with HIV, having more available drugs that work in different ways offers more options for putting together optimal regimens.

Some of the experimental agents discussed at CROI represent novel drug classes that work differently to existing antiretrovirals, including capsid inhibitors in early studies and monoclonal antibodies now in late-stage human trials.

Other presentations focused on next-generation candidates in familiar antiretroviral classes. Given that widely used approved drugs are very effective for HIV treatment, researchers are seeking incremental benefits in the areas of improved tolerability and convenience – such as long-acting drugs – as well as new options for HIV pre-exposure prophylaxis, or PrEP.



Source: www.aidsmap.com